Jump to Main Content
Identification of two antiviral inhibitors targeting 3C-like serine/3C-like protease of porcine reproductive and respiratory syndrome virus and porcine epidemic diarrhea virus
- Shi, Yuejun, Lei, Yingying, Ye, Gang, Sun, Limeng, Fang, Liurong, Xiao, Shaobo, Fu, Zhen F., Yin, Ping, Song, Yunfeng, Peng, Guiqing
- Veterinary microbiology 2018 v.213 pp. 114-122
- Porcine epidemic diarrhea virus, Porcine reproductive and respiratory syndrome virus, active sites, antiviral agents, antiviral properties, hydrogen bonding, hydrophobicity, median effective concentration, models, pathogens, proteinase inhibitors, serine proteinases, sterilizing immunity, swine, vaccines, virulence
- Porcine reproductive and respiratory syndrome virus (PRRSV) and porcine epidemic diarrhea virus (PEDV) are highly virulent and contagious porcine pathogens that cause tremendous economic losses to the swine industry worldwide. Currently, there is no effective treatment for PRRSV and PEDV, and commercial vaccines do not induce sterilizing immunity. In this study, we screened a library of 1000 compounds and identified two specific inhibitors, designated compounds 2 and 3, which target the PRRSV 3C-like serine protease (3CLSP). First, we evaluated the inhibitory effects of compounds 2 and 3 on PRRSV 3CLSP activity. Next, we determined the anti-PRRSV capacity of compounds 2 and 3 in MARC-145 cells and obtained EC50 and CC50 values of 57μM (CC50=479.9μM) and 56.8μM (CC50=482.8μM), respectively. Importantly, compounds 2 and 3 also targeted the PEDV 3C-like protease (3CL protease) and inhibited PEDV replication, showing EC50 and CC50 values of 100μM (CC50=533.8μM) and 57.9μM (CC50=522.3μM), respectively. Finally, our results indicated that the active sites (His39 in 3CLSP and His41 in 3CL protease) were conservative, and contacted compounds 2 and 3 via hydrogen bonds and hydrophobic forces in the putative substrate-binding models. In summary, compounds 2 and 3 exhibit broad-spectrum antiviral activity and may facilitate the development of antiviral drugs against PRRSV and PEDV.